Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
Vitrolife AB (publ) reports company news tied to IVF and reproductive-health products, with recurring updates on Consumables, Technologies and Genetics across EMEA, the Americas and APAC. Its releases include interim results, sales trends by product group and region, margin and cash-flow commentary, and developments in the group's efforts to connect products and services across the IVF workflow.
Company announcements also cover governance and capital actions, including annual general meeting notices and reports, leadership changes, refinancing facilities and strategic investments such as AutoIVF and its OvaReady automated system for egg retrieval and preparation.
Vitrolife AB (publ) has announced the appointment of its election committee for the Annual General Meeting in 2025. The committee members are:
- Niels Jacobsen, appointed by William Demant Invest A/S
- Patrik Tigerschiöld, appointed by Bure Equity AB
- Patricia Hedelius, appointed by AMF Fonder & Pension
- Jón Sigurdsson, Chairman of the Board
The appointments follow the principles determined at the Annual General Meeting on April 25, 2024. The upcoming Annual General Meeting will be held on April 29, 2025 in Gothenburg. Shareholders wishing to propose items for consideration must submit their requests to the Board at least seven weeks before the meeting.
Vitrolife AB (publ) reported strong Q2 2024 results, with sales reaching SEK 941 million, a 4% increase in both local currencies and SEK. The company saw significant growth in its Technologies business area, up 40% in local currencies. Gross margin improved to 59.9%, while EBITDA increased to SEK 327 million with a margin of 34.7%. Net income rose to SEK 143 million, resulting in earnings per share of SEK 1.06.
Regionally, EMEA led growth at 11%, followed by Americas at 5%, while APAC declined by 5%. Vitrolife also made strategic acquisitions, including EMB's distribution activities and eFertility. The first half of 2024 showed overall positive trends, with improved financial metrics across the board.
Vitrolife Group will host a conference call on July 17, 2024, at 10:00 a.m. CET to discuss its Q2 2024 interim report. Participants include CEO Bronwyn Brophy O'Connor and CFO Patrik Tolf. The interim report will be released at 8:00 a.m. CET on the same day, with presentation materials available on the company's website beforehand. Registration for the call is required, and a recorded version will be accessible via an international phone number for seven days. This announcement was made on July 3, 2024, from Gothenburg, Sweden.
Vitrolife AB has finalized the acquisition of eFertility, a system and software company specializing in IVF clinic management. eFertility, known for its eWitness and eBase solutions, operates mainly in the Netherlands and is expanding across Europe. In 2023, eFertility achieved revenues of EUR 1.5 million, reflecting the growing demand for IVF witnessing systems. eFertility will be integrated into Vitrolife's Technologies business area, as announced by CEO Bronwyn Brophy O'Connor on May 22, 2024.
Vitrolife AB (publ) has acquired 100% of the shares in eFertility, a system and software company focused on transforming IVF clinic management. The acquisition is part of Vitrolife Group's strategy to standardize and digitalize IVF clinics globally. eFertility offers innovative solutions like eWitness and eBase, with revenues of EUR 1.5 million in 2023. The purchase price is EUR 9.6 million with a potential earn-out of EUR 8.4 million over three years. The acquisition is expected to close in mid-May 2024, financed by Vitrolife Group's cash.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.